10-K: AlloVir to Merge with Kalaris Therapeutics After Discontinued Trials, Aims for KLRS Ticker

AlloVir plans to merge with Kalaris Therapeutics following the discontinuation of its Phase 3 trials, seeking to maximize shareholder value and trade under the ticker symbol KLRS upon completion.

Summary

• AlloVir discontinued Phase 3 trials of posoleucel due to futility analyses.
• The company is pursuing a merger with Kalaris Therapeutics to maximize shareholder value.
• AlloVir has reduced its workforce by approximately 95% as part of its strategic review.
• The merger agreement was signed on November 7, 2024, with Kalaris surviving as a wholly-owned subsidiary of AlloVir.
• Upon completion, AlloVir will change its name to Kalaris Therapeutics, Inc. and trade under the ticker symbol KLRS.
• Pre-merger Kalaris stockholders are expected to own approximately 75.34% of the combined company, while pre-merger AlloVir stockholders will own approximately 24.66%.
• The exchange ratio assumes a valuation of AlloVir at $116.0 million and Kalaris at $347.0 million, subject to adjustments based on AlloVirs net cash at closing.
• Kalaris is permitted to secure up to $15.0 million in additional financing prior to the merger, with AlloVir contributing up to $7.5 million.
• AlloVir provided Kalaris with a $3.75 million convertible promissory note as part of the first tranche of the Additional Permitted Bridge Financing.
• If the merger is terminated, AlloVir may be required to pay Kalaris a termination fee of $3.48 million, or Kalaris may be required to pay AlloVir a termination fee of $10.41 million.
• If the merger is not completed, AlloVir may pursue another strategic transaction, continue to operate its business, or dissolve and liquidate its assets.
• A special meeting of AlloVir stockholders is scheduled for March 12, 2025, to approve the merger and related matters.
• As of December 31, 2024, AlloVir had cash, cash equivalents, and short-term investments of $118.3 million.
• AlloVir believes that its existing cash, cash equivalents and short-term investments, will enable it to fund its operating expenses and capital expenditure requirements through at least twelve months following the issuance of these financial statements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the merger offers potential future value, the discontinued trials, workforce reduction, and ongoing losses contribute to a negative sentiment. The high degree of uncertainty surrounding the merger outcome further dampens the outlook.

Positives

• The merger with Kalaris is expected to create a combined company with promising science, a strong leadership team, and substantial capital resources.
• AlloVir is taking steps to maximize shareholder value through a strategic review process.
• The workforce reduction plan is expected to preserve capital and extend AlloVirs financial runway.
• The merger agreement has been unanimously approved by the AlloVir board of directors.

Negatives

• AlloVir discontinued Phase 3 trials of posoleucel due to futility analyses.
• AlloVir has incurred significant operating losses since its inception and expects to continue to incur losses for the foreseeable future.
• The company has a limited operating history, which may make it difficult to evaluate the success of its business to date and to assess its future viability.
• The company is considered a shell company under federal securities laws and is subject to more stringent reporting requirements.

Risks

• The merger may not be completed, and AlloVir may be required to pay a termination fee.
• The market price of AlloVirs common stock may be volatile.
• The combined company may not realize the anticipated benefits of the merger.
• AlloVirs securityholders and Kalaris securityholders will have a reduced ownership and voting interest in the combined company.
• Raising additional capital may cause dilution to the combined companys stockholders.
• AlloVir may become involved in litigation, including securities class action litigation.
• AlloVir may not be successful in consummating the merger.
• If the merger is not completed, AlloVirs board of directors may decide to pursue a dissolution and liquidation.
• AlloVirs cash preservation activities, including the workforce reduction plan, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt AlloVirs business.
• Transfers of the combined companys securities utilizing Rule 144 of the Securities Act may be limited.

Future Outlook

AlloVir expects to devote significant time and resources to the completion of the merger with Kalaris. If the merger is not completed, AlloVir will reconsider its strategic alternatives, which may include pursuing another strategic transaction, continuing to operate its business, or dissolving and liquidating its assets.

Management Comments

• AlloVir and Kalaris believe that combining the two companies will result in a combined company with promising science, a strong leadership team and substantial capital resources, positioning it to become a biopharmaceutical company focused on developing Kalaris lead product candidate, TH103.

Industry Context

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. AlloVir faces potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, and public and private research institutions.

Comparison to Industry Standards

• Atara Biotherapeutics, Inc.'s Ebvallo (tabelecleucel), an off-the-shelf, allogeneic T-cell immunotherapy, for HCT and SOT patients with EBV+PTLD (EBV-associated post-transplant lymphoproliferative disease), received European marketing authorization in December 2022.
• There are currently no FDA or EMA-approved antiviral therapies for treating most viral diseases and infections in the post-transplant setting, and current antiviral therapies are associated with significant toxicity, including renal insufficiency and bone marrow suppression.

Management Changes

Legal Proceedings

• A securities class action lawsuit has been filed against AlloVir and certain of its officers, alleging false and misleading statements and omissions relating to its Phase 3 posoleucel trials.
• A derivative lawsuit has been filed against certain of AlloVirs officers and directors, alleging violations of the Securities Exchange Act of 1934 and breach of fiduciary duty.
• A second derivative lawsuit has been filed against certain of AlloVirs officers and directors, alleging violations of Section 14(a) of the Securities Exchange Act of 1934, breach of fiduciary duties, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control against the individual defendants and contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 against Ms. Brainard and Mr. Sinha.

Related Party Transactions

• AlloVir has entered into a shared services agreement with ElevateBio, a holder of more than 5% of its voting securities, that provides for ongoing services to AlloVir in areas such as accounting operations, public relations, information technology, human resources and administration management, finance and risk management, marketing services, facilities, procurement and travel, and corporate development and strategy.
• AlloVir is party to a development and manufacturing services agreement with ElevateBio BaseCamp, pursuant to which BaseCamp provides AlloVir products and services that AlloVir uses in its laboratory operations, including consulting services, project management services, quality control services and cGMP drug product manufacturing.
• AlloVir is party to a services agreement with Marker Therapeutics, pursuant to which Marker provides AlloVir with development services. Juan Vera, a current director and former executive officer of AlloVir, is co-founder, director and chief development officer of Marker.

Stakeholder Impact

• Shareholders face uncertainty regarding the completion of the merger and the future value of their investment.
• Employees have been significantly impacted by the workforce reduction plan.
• Patients may experience delays in the development of new therapies due to the discontinued trials.
• Suppliers and creditors may be affected by the companys strategic review and potential liquidation of assets.

Next Steps

• AlloVir stockholders will vote on the merger agreement on March 12, 2025.
• AlloVir and Kalaris will work to satisfy the remaining closing conditions for the merger.
• If the merger is completed, the combined company will focus on developing Kalaris lead product candidate, TH103.
• If the merger is not completed, AlloVir will reconsider its strategic alternatives.

Key Dates